{
    "id": 962,
    "name": "neurofibroma",
    "source": "DOID",
    "definition": null,
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:962",
    "evidence": [
        {
            "id": 2183,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with PD-0325901 inhibited tumor growth in mouse models of neurofibroma with NF1 loss of expression (PMID: 23221341).",
            "molecularProfile": {
                "id": 5927,
                "profileName": "NF1 loss"
            },
            "therapy": {
                "id": 849,
                "therapyName": "PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 962,
                "name": "neurofibroma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2711,
                    "pubMedId": 23221341,
                    "title": "MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23221341"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT02096471",
            "title": "MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 849,
                    "therapyName": "PD-0325901",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02839720",
            "title": "Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Dermal Neurofibroma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 913,
                    "therapyName": "Selumetinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03259633",
            "title": "An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1",
            "phase": "Expanded access",
            "recruitment": "Available",
            "therapies": [
                {
                    "id": 913,
                    "therapyName": "Selumetinib",
                    "synonyms": null
                }
            ]
        }
    ]
}